Myelofibrosis Treatment | Market Size, Share & Growth Report 2024-2033

North America holds the largest disclosed revenue in this market and the approval that defines each product's position. Jakafi net product revenue rose 11% to USD 3.09 billion for the year ended 31 December 2025, driven by a 9% increase in paid demand, and that figure is United States revenue because the originator holds rights only in this territory. It also spans polycythemia vera and graft-versus-host disease alongside myelofibrosis, so only part of it belongs to this market. The regional ranking rests on that documented commercial and regulatory concentration rather than on a measured regional market size for myelofibrosis specifically. All four JAK inhibitors were first approved here, and the subgroup positioning that differentiates them, by platelet count and by anaemia, was established through FDA labelling.

Europe is supplied under a different corporate arrangement from North America, which is the defining feature of this market's geography. Ruxolitinib is marketed outside the United States by Novartis under the Jakavi name rather than by its originator, so the same molecule generates revenue for two independent companies in different territories and no single disclosure covers the global product. Momelotinib is marketed in Europe as Omjjara. The region also hosts the acquirer of the pacritinib franchise, following Sobi's completion of the CTI BioPharma transaction on 26 June 2023. No European market size, revenue or growth figure specific to myelofibrosis was identified among the sources examined.

No market size, revenue or growth figure specific to Asia Pacific was identified for myelofibrosis, and none of the companies examined discloses the region separately for these products. The structural position is that myelofibrosis is a rare myeloproliferative neoplasm diagnosed through bone marrow biopsy and molecular testing for JAK2, CALR and MPL mutations, so the treated population in any country is bounded by access to that diagnostic pathway rather than by disease frequency. Where molecular haematology is concentrated in a small number of centres, patients reach a JAK inhibitor later and in smaller numbers. The oral route removes an administration barrier but not a diagnostic one.

No market size, revenue or growth figure specific to Latin America was identified, and no company examined reports the region separately for these products. The commercial position is that all four approved agents are branded specialty oncology drugs with no generic alternative until ruxolitinib exclusivity ends in December 2028, so affordability rather than availability is the constraint. Allogeneic stem cell transplantation, the only potentially curative option, requires transplant capacity that is unevenly distributed. The practical consequence is that patients in the region are more likely to be managed with transfusion support and older cytoreductive agents, which sit in the Others value of the supplied Drug Type segmentation rather than in the four named ones.

No market size, revenue, prescribing or access figure specific to the Middle East and Africa was identified for this market. The same two constraints described for other lower-access regions apply and compound here: myelofibrosis requires bone marrow biopsy with molecular mutation testing to diagnose, and the four approved treatments are branded specialty drugs priced accordingly. A patient who is not tested is not diagnosed, and a patient who is diagnosed may still not be treated with a JAK inhibitor. The region therefore contributes very little to a market whose value depends on sustained branded prescribing to a correctly identified rare-disease population.